Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
siRNA targeting CD44 V5
- Development stage
- Unknown
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Intratumoral, Intravenous, Intraperitoneal, Parenteral
01
Overview
siRNA targeting CD44 V5 is a research-use-only short interfering RNA (siRNA) designed to knock down the expression of the CD44 variant 5 (CD44v5) isoform. CD44v5 is an alternative splicing variant of the CD44 cell-surface glycoprotein, which has been implicated in tumor cell migration, invasion, and metastasis in various cancers, including renal cell carcinoma, cervical carcinoma, and breast cancer. In preclinical studies, transfection of CD44v5 siRNA has been utilized to investigate the role of this specific isoform in growth factor-induced cell migration and resistance to apoptosis, demonstrating that while CD44v5 may regulate migration in certain cell types, its knockdown does not significantly alter sensitivity to doxorubicin or Fas-mediated apoptosis in breast cancer initiating cells.
- Other names
- CD44 V5 siRNACD-44 V5 siRNACD 44 V5 siRNACD44v5 siRNACD-44v5 siRNACD 44v5 siRNAsiRNA targeting CD44 variant 5siRNA targeting CD44v5
02
Targets
CD44 (CD44 antigen)
Beyond the preview
Go deeper on siRNA targeting CD44 V5.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on siRNA targeting CD44 V5.